We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 27, 2022

Effect of Expanded Dulaglutide Weekly Doses on CVD Risk Factors in Participants With Type 2 Diabetes at Increased CVD Risk

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
Diabetes Obes Metab 2022 Sep 01;24(9)1770-1778, DA Cox, H Wang, C Nicolay, MA Bethel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading